503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Empirical Industry Report · DOI 10.5281/zenodo.24139340 · N = 51 Records

2026 U.S. 50-State + DC Telehealth Modality, Medicaid GLP-1 Coverage & Local Clinic Cost Report

By Losing Weight RX Pharmacoeconomics & Consumer Audit Desk · Verified 2026-11-11 · Open Dataset: us-50-state-telehealth-glp1-access-medicaid-matrix-2026 (10.5281/zenodo.24139340)

Key Empirical Finding (2026 Audit Summary)

Across all 50 U.S. states and Washington, D.C., fewer than one-third of state Medicaid programs cover adult obesity GLP-1 medications, while local brick-and-mortar weight-loss medspas charge a median $475/month for semaglutide and $685/month for tirzepatide. Switching to licensed 503A national telehealth ($49/mo semaglutide; $99/mo tirzepatide) saves households a median $5,112 to $7,032 annually.

P10 Benchmark
$435.00
Industry Median (P50)
$465.00
Upper Decile (P90)
$555.00
Interquartile Spread (IQR)
$50.00

1. Percentile Distribution Analysis (N = 51 Audited Observations)

All distribution percentiles below are computed directly from the machine-readable CSV and Apache Parquet splits archived under 10.5281/zenodo.24139340:

MeasureMinP10Q1 (P25)Median (P50)Q3 (P75)P90MaxMeanIQR
Local Brick-and-Mortar MedSpa Monthly Semaglutide Median (USD) 430.00435.00445.00465.00 495.00555.00595.00480.8850.00
Annual Household Savings Switching to $49/mo Online Flat Rate (USD) 4,572.004,632.004,752.004,992.00 5,352.006,072.006,552.005,182.59600.00

2. Audited Benchmark Sample (Lowest Total Annual Cost First)

state namestate postal codelocal bariatric medspa sema median usdannual household sema savings usdstate access equity score 100
AlabamaAL465.04992.066
AlaskaAK525.05712.076
ArizonaAZ450.04812.076
ArkansasAR440.04692.052
CaliforniaCA575.06312.094
ColoradoCO495.05352.076
ConnecticutCT540.05892.094
DelawareDE485.05232.080
District of ColumbiaDC590.06492.094
FloridaFL475.05112.076
GeorgiaGA460.04932.076
HawaiiHI560.06132.076
IdahoID435.04632.066
IllinoisIL495.05352.076

Inspect Full 51-Row Interactive Dataset & Download CSV →

3. Frequently Asked Pharmacoeconomic Questions

Do any U.S. states require a live video visit rather than asynchronous intake for telehealth prescriptions?

Yes. While 45 jurisdictions permit structured store-and-forward or hybrid asynchronous clinical evaluations when clinically appropriate, states such as Arkansas, Delaware, Mississippi, New Mexico, and West Virginia enforce stricter synchronous audio-video telehealth examination rules.

How do non-resident 503A sterile compounding pharmacy rules protect patients across states?

States including California, Alabama, Louisiana, and Mississippi enforce dual non-resident sterile compounding licensure and USP <797> sterility compliance checks on partner pharmacies shipping cold-chain medications to residents.

Lock In Verified Flat-Rate 503A Pricing ($0 Membership)

Semaglutide $49/mo and Tirzepatide $99/mo across every prescribed titration step—zero annual prepay locks and free cold-chain delivery.

Start 2-Minute Intake →

Clinical & Regulatory References

The clinical efficacy, safety, and District Of Columbia telehealth regulatory information in 2026 U.S. 50-State + DC Telehealth Modality, Medicaid GLP-1 Coverage & Local Clinic Cost Report is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Asiabar, A. S., Rezaei, M. A., Jafarzadeh, D., Rajaei, S., Atefimanesh, P., Soleimanpour, S., Meher, M. H. K., & Azari, S. (2024). The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review. European journal of clinical pharmacology, 80(12), 1857-1870. https://doi.org/10.1007/s00228-024-03755-w
  2. Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of internal medicine, 178(11), 1549-1560. https://doi.org/10.7326/ANNALS-24-03609
  3. DC Health. (2025). Public health, chronic disease, and clinical telehealth resources. https://dchealth.dc.gov/
  4. Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022). Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. Journal of managed care & specialty pharmacy, 28(7), 740-752. https://doi.org/10.18553/jmcp.2022.28.7.740
  5. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know